TyrNovo

About

TyrNovo is developing a cancer treatment that eliminates a key protein, an approach that has the potential to improve cancer therapy, prevent drug resistance, and increase life expectancy. The companys novel approach promotes the degradation of insulin-receptor substrates 1 and 2. While targeted anticancer drugs inhibit the on signal, TyrNovos compounds activate the off switch, extensively blocking major oncogenic pathways. The compounds NT157 and NT219 have been licensed exclusively by TyrNovo from Yissum Research Development Company of the Hebrew University of Jerusalem. TyrNovos activity has been entirely integrated into Kitov Pharmaceuticals.

Facts

Acquisitions (1)

Team (1)

News mentions (3)

1. Jan 13, 2017 — www.prnewswire.com: Article
2. Dec 9, 2015 — www.jpost.com: Article
3. Dec 9, 2015 — medicalxpress.com: Article